LITAF, HHEX, and DUSP1 expression in mesenchymal stem cells from patients with psoriasis

Abstract

ABSTRACT. Psoriasis is a common chronic relapsing inflammatory skin disease, in which mesenchymal stem cells (MSCs) have been hypothesized to play an important role in abnormal localized inflammation and vascular proliferation observed in skin lesions. Previous studies have revealed abnormal gene expression patterns, DNA methylation status, and cytokine secretion of MSCs in psoriatic skin lesions, as well as some gene expression abnormalities related to inflammation and angiogenesis. We further verified the gene and protein expressions of inflammation-related lipopolysaccharide-induced tumor necrosis factor-alpha transcription factor (LITAF), dual-specificity protein phosphatase 1 (DUSP1), and angiogenesis-related hematopoietically expressed homeobox (HHEX) in MSCs derived from the skin lesions of psoriasis patients. The gene expression of LITAF, DUSP1, and HHEX in dermal MSCs was measured at the mRNA level using reverse transcription-polymerase chain reaction and the corresponding protein expression levels were analyzed by western (2015) blotting analysis. The gene and protein expression levels of LITAF, HHEX, and DUSP1 in dermal MSCs were significantly lower in psoriasis patients compared to controls. Amplification and western blotting results were consistent with our previously reported gene chip data. Our results suggest that dermal MSCs in psoriatic skin lesions may be involved in the development, progression, and regulation of localized inflammatory abnormalities by reducing the expression of LITAF, HHEX, and DUSP1, which are related to inflammation and angiogenesis.

Increased miR-155-5p expression in dermal mesenchymal stem cells of psoriatic patients: comparing the microRNA expression profile by microarray

“…Dermal MSCs were isolated and expanded as described in previous studies (Hou et al, 2014, Chang et al, 2015. Non-adherent cells were removed after 48 h, and half the medium was changed every 3-4 days.…”

“…We have previously reported that some inflammation-and angiogenesis-related genes, such as IL-1β, CXCL14, VEGFα, GATA-6, insulin-like growth factor-binding protein-5 (IGFBP5), lipopolysaccharide-induced tumor necrosis factor-alpha transcription factor (LITAF), and dual-specificity protein phosphatase 1 (DUSP1), are significantly differentially expressed in dermal MSCs from patients with psoriasis (Liu et al, 2013;Hou et al, 2014;Chang et al, 2015). Psoriatic dermal MSCs present an impaired capacity to inhibit T cell proliferation (Liu et al, 2014).…”

Levels of miR‐31 and its target genes in dermal mesenchymal cells of patients with psoriasis

“…A two‐step method was adopted to separate DMSCs. First, the skin samples were cut into small pieces of approximately 1 mm, which were then digested using 0.25% Dispase enzyme II (Sigma, St. Louis, MO, USA) at 4 °C overnight. Second, the epidermis and dermis were separated using mechanical methods, and the dermis was then minced.…”

“…After 72 hours, the culture medium was changed to remove the cells in suspension. Then, half of the old culture medium was replaced with fresh medium every 3 days . We harvested the 5th generation of cells to identify whether these cells were DMSCs .…”

“…MSCs play a role not only in immunoregulation but also in causing proangiogenic effects and vascular proliferation, the two most evident pathological changes in psoriasis. MSCs negatively regulate immune responses, inhibit the activity of T lymphocytes, and express vascular endothelial growth factor (VEGF), which facilitates local angiogenesis . In a previous study, abnormal cytokine secretion in DMSCs derived from dermal lesions of patients with psoriasis has been found to induce the proliferation of keratinocytes (KCs) and downregulate apoptosis, resulting in local dermal incrassation.…”